Veracyte, Inc. (VCYT) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$40.76
Price Target
$44.50
Target Range
$37.00 — $50.00
Analyst Rating
Buy
Forward P/E24.6x
Trailing P/E49.7x
Forward PEG—
Implied Growth+53.3%
Median Target$45.50
Analyst Spread29.2%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$37
-9.2%
Consensus
$45
+9.2%
Bull Case
$50
+22.7%
VCYT Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Veracyte, Inc. (VCYT) has a Wall Street consensus price target of $44.50, based on estimates from 20 covering analysts. With the stock currently trading at $40.76, this represents a potential upside of +9.2%. The company has a market capitalization of $3.25B.
Analyst price targets range from a low of $37.00 to a high of $50.00, representing a 29% spread in expectations. The median target of $45.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 13 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, VCYT trades at a trailing P/E of 49.7x and forward P/E of 24.6x. Analysts expect EPS to grow +53.3% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+8.0%
Avg Forward P/E89.9x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 EXASExact Sciences Corporation | $20.0B | $104.91 | $103.18 | -1.6% | Buy | 582.8x | 41 |
 NTRANatera, Inc. | $31.2B | $219.82 | $262.50 | +19.4% | Buy | — | 27 |
 CDNACareDx, Inc | $1.1B | $21.44 | $24.00 | +11.9% | Buy | 22.8x | 13 |
 ACNBACNB Corporation | $549M | $53.00 | $58.00 | +9.4% | Buy | 9.9x | 2 |
 PAHCPhibro Animal Health Corporation | $1.7B | $43.16 | $49.00 | +13.5% | Buy | 14.2x | 13 |
 ILMNIllumina, Inc. | $21.1B | $138.71 | $147.38 | +6.3% | Buy | 26.8x | 50 |
 TMOThermo Fisher Scientific Inc. | $176.4B | $474.56 | $654.67 | +38.0% | Buy | 19.1x | 42 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $79.00 | +3.9% | Hold | 17.2x | 42 |
 NEOGNeogen Corporation | $2.0B | $9.25 | $11.00 | +18.9% | Hold | 25.9x | 11 |
 PACBPacific Biosciences of California, Inc. | $498M | $1.65 | $1.00 | -39.4% | Buy | — | 18 |
Upside Potential Comparison
TMONTRANEOGPAHCCDNAACNBILMNHOLXSee VCYT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VCYT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VCYT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVCYT — Frequently Asked Questions
Quick answers to the most common questions about buying VCYT stock.
What is the VCYT stock price target for 2026?
The consensus price target for VCYT is $44.5, close to the current price of $40.76 (9.2% implied move). Based on 20 analyst estimates, the stock appears fairly valued near current levels.
Is VCYT a buy, sell, or hold?
VCYT has a consensus rating of "Buy" based on 20 Wall Street analysts. The rating breakdown is predominantly bullish, with 13 Buy/Strong Buy ratings. The consensus 12-month price target of $44.5 implies 9.2% upside from current levels.
Is VCYT stock overvalued or undervalued?
VCYT trades at a forward P/E of 24.5705x, representing a moderate valuation. With analysts targeting $44.5 (9.2% implied move), the stock appears reasonably valued with upside.
How high can VCYT stock go?
The most bullish Wall Street analyst has a price target of $50 for VCYT, while the most conservative target is $37. The consensus of $44.5 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover VCYT stock?
VCYT is well covered by analysts, with 20 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 13 have Buy ratings, 6 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the VCYT stock forecast?
The 12-month VCYT stock forecast based on 20 Wall Street analysts shows a consensus price target of $44.5, with estimates ranging from $37 (bear case) to $50 (bull case). The median consensus rating is "Buy".
What is VCYT's forward P/E ratio?
VCYT trades at a forward P/E ratio of 24.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 49.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy VCYT stock?
VCYT appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $44.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do VCYT price targets vary so much?
VCYT analyst price targets range from $37 to $50, a 29% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $44.5 consensus represents the middle ground.